Close Menu


The firm presented evidence that its DetermaIO gene expression test can help predict which bladder cancer patients are likely to respond to immune checkpoint inhibitors.

Researchers said that the score further may identify patients whose treatment resistance may be overcome with combination strategies targeting certain cells.

If the team is successful in expanding on the results that they reported last month, it could open a new application for the still nascent circulating tumor DNA technology.

Investigators flagged a set of myeloma-defining genomic events that marked precursor conditions that were prone to morph into multiple myeloma.

The results represent a significant improvement over currently used screening tools and are spurring renewed LDT commercialization and regulatory submission efforts.